Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2014, Article ID 679605, 6 pages
http://dx.doi.org/10.1155/2014/679605
Clinical Study

Nephrogenic Systemic Fibrosis Risk and Liver Disease

1Department of Radiology, Columbia University, New York Presbyterian Hospital, 622 West 168th Street, PB-1-301, New York, NY 10032, USA
2Division of Liver Diseases, Department of Pathology, Columbia University, 622 West 168th Street, New York, NY, USA

Received 8 November 2013; Revised 2 February 2014; Accepted 17 February 2014; Published 23 March 2014

Academic Editor: Anil K. Agarwal

Copyright © 2014 Robert F. Hanna et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” The New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. L. L. Wong, “Current status of liver transplantation for hepatocellular cancer,” The American Journal of Surgery, vol. 183, no. 3, pp. 309–316, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. United Network for Organ Sharing, “Organ distribution: allocation of livers,” Policy 3.6, 2010, http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp. View at Google Scholar
  5. A. Colli, M. Fraquelli, G. Casazza et al., “Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review,” The American Journal of Gastroenterology, vol. 101, no. 3, pp. 513–523, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. S. E. Cowper, H. S. Robin, S. M. Steinberg, L. D. Su, S. Gupta, and P. E. LeBoit, “Scleromyxoedema-like cutaneous diseases in renal-dialysis patients,” The Lancet, vol. 356, no. 9234, pp. 1000–1001, 2000. View at Google Scholar · View at Scopus
  7. T. Grobner, “Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?” Nephrology Dialysis Transplantation, vol. 21, no. 4, pp. 1104–1108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Marckmann, L. Skov, K. Rossen et al., “Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging,” Journal of the American Society of Nephrology, vol. 17, no. 9, pp. 2359–2362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Perez-Rodriguez, S. Lai, B. D. Ehst, D. M. Fine, and D. A. Bluemke, “Nephrogenic systemic flbrosis: incidence, associations, and effect of risk factor assessment—report of 33 cases,” Radiology, vol. 250, no. 2, pp. 371–377, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Altun, D. R. Martin, R. Wertman, A. Lugo-Somolinos, E. R. Fuller III, and R. C. Semelka, “Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy—report from two U.S. universities,” Radiology, vol. 253, no. 3, pp. 689–696, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. EMEA, “Assessment report for Gadolinium-containing contrast agents,” Assessment Report EMEA/H/A-31/1097, 2010, http://www.lsw.uni-heidelberg.de/users/christlieb/teaching/UKStaSS10/R-refman.pdf. View at Google Scholar
  12. S. M. Mazhar, M. Shiehmorteza, C. A. Kohl, M. S. Middleton, and C. B. Sirlin, “Nephrogenic systemic fibrosis in liver disease: a systematic review,” Journal of Magnetic Resonance Imaging, vol. 30, no. 6, pp. 1313–1322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R Development Core Team, R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, 2013.
  14. A. Gelman, J. B. Carlin, H. S. Stern, and D. B. Rubin, Bayesian Data Analysis, Chapman & Hall, London, UK, 1997.
  15. A. S. Befeler, P. H. Hayashi, and A. M. di Bisceglie, “Liver transplantation for hepatocellular carcinoma,” Gastroenterology, vol. 128, no. 6, pp. 1752–1764, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Bharat, D. B. Brown, J. S. Crippin et al., “Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival,” Journal of the American College of Surgeons, vol. 203, no. 4, pp. 411–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Hueper, M. Elalfy, F. Laenger et al., “PET/CT imaging of c-Myc transgenic mice identifies the genotoxic N-Nitroso-Diethylamine as carcinogen in a Short-Term cancer bioassay,” PLoS ONE, vol. 7, no. 2, Article ID e30432, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. S. E. Kim, H. C. Lee, J. H. Shim et al., “Noninvasive diagnostic criteria for hepatocellular carcinoma in hepatic masses >2 cm in a hepatitis B virus-endemic area,” Liver International, vol. 31, no. 10, pp. 1468–1476, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. S. Boyd, J. A. Zic, and J. L. Abraham, “Gadolinium deposition in nephrogenic fibrosing dermopathy,” Journal of the American Academy of Dermatology, vol. 56, no. 1, pp. 27–30, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Maloo, P. Abt, R. Kashyap et al., “Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update,” American Journal of Transplantation, vol. 6, no. 9, pp. 2212–2217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Chiu, G. Wells, H. Carag, E. Canova, and R. J. Firpi, “Nephrogenic fibrosing dermopathy: a rare entity in patients awaiting liver transplantation,” Liver Transplantation, vol. 10, no. 3, pp. 465–466, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. Nephrogenic Systemic Fibrosis: Attorneys Experienced in Drug Product Liability and Medical Malpractice Cases, 2011, http://www.rcrsd.com/dangerous-medical-devices/gadolinium-nsf/.
  23. E. A. Sadowski, L. K. Bennett, M. R. Chan et al., “Nephrogenic systemic fibrosis: risk factors and incidence estimation,” Radiology, vol. 243, no. 1, pp. 148–157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. D. S. Sherman, D. N. Fish, and I. Teitelbaum, “Assessing renal function in cirrhotic patients: problems and pitfalls,” American Journal of Kidney Diseases, vol. 41, no. 2, pp. 269–278, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. C. K. Ng, M. H. M. Chan, M. H. L. Tai, and C. W. K. Lam, “Hepatorenal syndrome,” The Clinical Biochemist Reviews, vol. 28, no. 1, pp. 11–17, 2007. View at Google Scholar
  26. M. R. Prince, H. Zhang, M. Morris et al., “Incidence of nephrogenic systemic fibrosis at two large medical centers,” Radiology, vol. 248, no. 3, pp. 807–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Z. Zou and L. Ma, “Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases,” Indian Journal of Dermatology, vol. 56, no. 1, pp. 65–73.